{
  "abstract": "BackgroundDespite the high stroke burden in the elderly, their thrombolysis utilization is suboptimal partly due to heightened hemorrhagic risk. Observational data suggest that low-dose thrombolysis may offer comparable efficacy to standard-dose with a trend toward reduced symptomatic intracranial hemorrhage (sICH), yet high-level evidence for low-dose thrombolysis in this broad population remains absent.\n\nObjectiveTo evaluate the safety and efficacy of low-dose intravenous tenecteplase thrombolysis in elderly stroke patients within 4.5 hours of ischaemic stroke onset.\n\nMethods and designThe DATE-AGING trial is a multicenter, prospective, randomized, open-label, blinded-end point (PROBE) non-inferiority study. Eligible participants are elderly patients (aged [≥]70 years) with acute ischemic stroke who meet current guideline recommendations for intravenous thrombolysis within 4.5 hours of symptom onset will be randomly assigned to Low-dose Tenecteplase group (0.175 mg/kg, max 17.5 mg) or Standard-dose Tenecteplase group (0.25 mg/kg, max 25 mg). The primary outcome is excellent functional outcome, defined as modified Rankin Scale(mRS) 0-1 at 90 days. Safety outcomes include sICH within 36 hours and mortality at 90 days.\n\nDiscussionsThe DATE-AGING trial is intended to provide high-quality evidence for low-dose tenecteplase intravenous thrombolysis in elderly patients with acute ischemic stroke.\n\nTrial registry numberNCT07294209.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurology, First Affiliated Hospital of Army Medical University (Southwest Hospital), Chongqing, China"
  ],
  "article_type": "PUBLISHAHEADOFPRINT",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Z. Zhou"
    },
    {
      "name": "X. Hou"
    },
    {
      "name": "S. Mi"
    },
    {
      "name": "X. Chen"
    },
    {
      "name": "Y. He"
    },
    {
      "name": "L. Chen"
    },
    {
      "name": "Q. Liu"
    },
    {
      "name": "J. Wu"
    },
    {
      "name": "T. Lv"
    },
    {
      "name": "L. Kong"
    },
    {
      "name": "R. Xu"
    },
    {
      "name": "M. Wu"
    },
    {
      "name": "D. Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/370sxj1wkfwpq.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.08.26361416",
  "fulltext_url": "https://www.medrxiv.org/content/10.64898/2026.10.08.26361416v1.full",
  "id": "370sxj1wkfwpq",
  "issns": [],
  "landing_url": "https://www.medrxiv.org/content/10.64898/2026.10.08.26361416v1",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "medrxiv",
      "neurology"
    ],
    [
      "openalex",
      "2713|Acute Ischemic Stroke Management"
    ]
  ],
  "openalex": "W7221472889",
  "pdf_url": "https://www.medrxiv.org/content/10.64898/2026.10.08.26361416v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-08",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/370sxj1wkfwpq.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:38Z",
      "native_id": "10.64898/2026.10.08.26361416",
      "source": "medrxiv",
      "url": "https://www.medrxiv.org/content/10.64898/2026.10.08.26361416v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "medrxiv:neurology",
      "subfield": "neurology"
    }
  ],
  "title": "Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients DATE-AGING Trial: Rationale and Design",
  "title_text": "Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients DATE-AGING Trial: Rationale and Design",
  "type": "preprint",
  "updated_at": "2026-10-30T12:20:38Z",
  "url": "https://research.draconitic.com/paper/370sxj1wkfwpq",
  "venue": "medRxiv",
  "versions": []
}